by Swaminathan S, Pécoul B, Abdullah H, Christou C, Gray G, IJsselmuiden C, Kieny M-P, Mazzucato M, von Messling V, Ogutu B, Reeder J, Røttingen J-A, Swarup R, Tanner M, Lima NT, Childs M, Harris A, Torreele E, Moon S. Nature 2022;602:207-210 doi: https://doi.org/10.1038/d41586-022-00324-y
Summary: Challenges in ensuring global, equitable access to the fruits of biomedical research and development (R&D) during the COVID-19 pandemic have highlighted the urgency of reorienting the system towards the public interest. The authors of this comment seek to articulate a more holistic vision by asking three critical questions: Why do R&D? How should it be done, and for whom? DNDi is mentioned in several places, including our general approach to R&D and specific projects such as the COVID-19 Clinical Research Coalition and COVID Moonshot. Stakeholders are urged to collaborate on a checklist of nine actions for R&D in the global public interest.
